J. F. Timp, S. K. Braekkan, H. H. Versteeg, and S. C. Cannegieter, Epidemiology of cancer associated venous thrombosis, Blood, vol.122, pp.1712-1735, 2013.

C. Ay, I. Pabinger, and A. T. Cohen, Cancer associated venous thromboembolism:burden, mechanisms, and management, Thromb Haemost, vol.117, pp.219-249, 2017.

J. W. Blom, C. Doggen, S. Osanto, and F. R. Rosendaal, Malignancies, prothrombotic mutations, and the risk of venous thrombosis, JAMA. 9 févr, vol.293, issue.6, pp.715-737, 2005.

P. Prandoni, A. Lensing, and A. Piccioli, Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis, Blood, vol.100, pp.3484-3492, 2002.

S. Z. Goldhaber, E. Dricker, J. E. Buring, K. Eberlein, J. J. Godleski et al., Clinical suspicion of autopsy-proven thrombotic and tumor pulmonary embolism in cancer patients, American Heart Journal. 1 déc, vol.114, issue.6, pp.1432-1437, 1987.

A. A. Khorana, C. W. Francis, E. Culakova, N. M. Kuderer, and G. H. Lyman, Frequency, riskfactors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer, vol.110, pp.2339-2385, 2007.

J. F. Timp, S. K. Braekkan, H. H. Versteeg, and S. C. Cannegieter, Epidemiology of cancerassociated venous thrombosis, Blood, vol.122, issue.10, pp.1712-1735, 2013.

C. Milsom, J. Yu, and N. Mackman, Tissue Factor regulation by Epidermal Growth Factor Receptor and epithelial-to mesenchymal transitions: Effect on tumor initiation and angiogenesis, Cancer Res, vol.68, pp.10068-76, 2008.

D. Morris, Y. Ding, and T. Ricks, Protease-activated receptor-2 is essential for factor VIIa and Xainduced signalling migration, and invasion of breast cells, Cancer Res, vol.66, pp.307-321, 2006.

. Jiangx, S. Zhu, and T. Panetti, Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of tumor breast cancer cells, Thromb Heamost, vol.100, pp.127-160, 2008.

A. Falanga, T. Barbui, and F. Rickles, Hypercoagulability and tissue factor geneupregulation in hematologic malignancies, Semin Thromb Hemost, vol.34, pp.204-214, 2008.

. May, X. He, and H. Wang, Interaction of coagulation factors and tumor-associatedmacrophages mediates migration and invasion of gastric cancer, Cancer Sci, vol.102, pp.336-378, 2011.

G. Thomas, L. Panicot-dubois, and R. Lacroix, Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand-1 accelerate thrombus formation in vivo, JExp Med, vol.206, pp.1913-1940, 2009.

P. Fernandez, S. Patierno, and F. Rickles, Tissue factor and fibrin in tumor angiogenesis, Semin Thromb Hemost, vol.30, pp.31-44, 2004.

K. Kaplinska, M. Rozalski, and U. Krajewska, Cancer procoagulant (CP) analysis inhuman WM11 malignant melanoma cells in vitro, Thromb Res, vol.124, pp.364-371, 2009.

M. Demers, D. S. Krause, D. Schatzberg, K. Martinod, J. R. Voorhees et al., Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis, Proc Natl Acad Sci, vol.109, issue.32, pp.13076-81, 2012.

J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin et al., Heparin and lowmolecular-weight heparin : mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety, Chest, vol.119, issue.1, pp.64-94, 2001.

J. B. Hansen, P. M. Sandset, K. R. Huseby, N. E. Huseby, B. Bendz et al., Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor : evidence for a difference in antithrombotic action, Br J Haematol, vol.101, pp.638-684, 1998.

B. Bendz, J. B. Hansen, T. O. Andersen, P. Ostergaard, and P. M. Sandset, Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not withtwo low molecular weight heparins, Br J Haematol, vol.107, pp.756-62, 1999.

P. M. Sandset, B. Bendz, and J. B. Hansen, Physiological function of tissue factor pathway inhibitor and interaction with heparins, Haemostasis, vol.30, pp.48-56, 2000.

J. Rey and V. Launay-vacher, Utilisation des héparines de bas poids moléculaire (HBPM) chez le patient insuffisant rénal en milieu hospitalier, Journal de Pharmacie Clinique. 1 juin, vol.30, issue.2, pp.61-74, 2011.

N. J. Short and J. M. Connors, New oral anticoagulants and the cancerpatient, Oncologist, vol.19, pp.82-93, 2014.

S. Schulman, C. Kearon, A. K. Kakkar, P. Mismetti, . Schellongs et al., Dabigatran versus warfarin in thetreatment of acute venous thromboembolism, N Engl J, vol.361, pp.2342-52, 2009.

S. Schulman, A. K. Kakkar, S. Z. Goldhaber, S. Schellong, H. Eriksson et al., Treatment of acute venous thromboembolismwith dabigatran or warfarin and pooled analysis, vol.129, p.12, 2014.

E. Investigators, R. Bauersachs, S. D. Berkowitz, B. Brenner, H. R. Büller et al., Oral rivaroxaban for symptomaticvenous thromboembolism, N Engl J Med, vol.363, pp.2499-510, 2010.

E. Investigators, H. R. Büller, M. H. Prins, A. Lensin, H. Decousus et al., Oral rivaroxaban for the treat-ment of symptomatic pulmonary embolism, N Engl J, vol.366, pp.1287-97, 2012.

G. Agnelli, H. R. Büller, A. Cohen, M. Curto, A. S. Gallus et al., Oral apixaban for the treatment of acute venousthromboembolism, N Engl J Med, vol.369, pp.799-808, 2013.

I. Hokusai, -. Büller, H. R. Décousus, H. Grosso, M. A. Mercuri et al.,

, Edoxaban versus warfarin forthe treatment of symptomatic venous thromboembolism, NEngl J Med, vol.369, pp.1406-1421, 2013.

G. E. Raskob, N. Van-es, P. Verhamme, M. Carrier, D. Nisio et al., Hokusai VTE cancer investigators. Edoxaban for thetreatment of cancer-associated venous thromboembolism, NEngl J Med, vol.378, pp.615-639, 2018.

A. M. Young, A. Marshall, J. Thirlwall, O. Chapman, A. Lokare et al., Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D), J Clin Oncol. 10 juill, vol.36, issue.20, pp.2017-2040, 2018.

A. Li, D. A. Garcia, G. H. Lyman, and M. Carrier, Direct oral anticoagulant (DOAC) versus low-molecularweight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis, Thromb Res. 2 mars, 2018.

A. A. Khorana, Evaluation of US prescription patterns: Are treatment guidelines for cancerassociated venous thromboembolism being followed?, Thromb Res, vol.145, pp.51-54, 2016.

G. H. Lyman, Venous thromboembolism prophylaxis and treatment in patients with cancer

, ASCO Clinical Practice Guideline Update, J. Clin Oncol, vol.31, pp.2189-2204, 2013.

. Farge, International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, J. Thromb Haemost, vol.11, pp.56-70, 2013.

A. Palumbo, S. V. Rajkumar, M. A. Dimopoulos, P. G. Richardson, S. Miguel et al., Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma, Leukemia. févr, vol.22, issue.2, pp.414-437, 2008.

A. Palumbo, M. Cavo, S. Bringhen, E. Zamagni, A. Romano et al., Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial, J Clin Oncol. 10 mars, vol.29, issue.8, pp.986-93, 2011.

N. Van-es, D. Nisio, M. Cesarman, G. Kleinjan, A. Otten et al., Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study

, Haematologica, vol.102, issue.9, pp.1494-501, 2017.

. Khorana, Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study, Cancer, vol.104, pp.2822-2831, 2005.

M. Mandalà, A. Falanga, F. Roila, and . Group, Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines, Ann Oncol, vol.22, issue.6, pp.85-92, 2011.

. Streiffmb, P. L. Bockenstedt, and S. R. Cataland, Venous thromboembolic disease, J Natl Compr Canc Netw, vol.9, issue.07, pp.714-777, 2011.

G. H. Lyman, K. Bohlke, and A. A. Khorana,

, Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update, J Clin Oncol, vol.33, issue.06, pp.654-656, 2014.

D. Farge, H. Bounameaux, and B. Brenner, International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer, Lancet Oncol, vol.17, issue.10, pp.452-466, 2016.

C. Kearon, E. A. Akl, and J. Ornelas, Antithrombotic therapy for VTE disease. CHEST guidelines and expert panel report, Chest, vol.149, issue.02, pp.315-352, 2016.

E. A. Akl, S. R. Vasireddi, S. Gunukula, M. Barba, F. Sperati et al.,

, Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer

, Cochrane Database Syst Rev, issue.6, p.6649, 2011.

. Prepic-study-group, Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation, vol.112, pp.416-438, 2005.

M. L. Louzada, M. Carrier, A. Lazo-langner, V. Dao, M. J. Kovacs et al., Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism, Circulation. 24 juill, vol.126, issue.4, pp.448-54, 2012.

R. D. Hull, G. F. Pineo, R. F. Brant, A. F. Mah, N. Burke et al.,

G. Poon and . Raskob, Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer, Am. J. Med, vol.119, issue.12, pp.1062-1072, 2006.

S. R. Deitcher, C. M. Kessler, G. Merli, J. R. Rigas, R. M. Lyons et al., Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period, Clin. Appl. Thromb. Hemost, vol.12, issue.4, pp.389-396, 2006.

A. Y. Lee, P. W. Kamphuisen, G. Meyer, R. Bauersachs, M. S. Janas et al., Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial, CATCH Investigators, vol.314, pp.677-686, 2015.

E. A. Akl, L. Kahale, M. Barba, I. Neumann, N. Labedi et al.,

. Schünemann, Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer, Cochrane Database Syst. Rev, vol.7, p.6650, 2014.

C. W. Francis, C. M. Kessler, S. Z. Goldhaber, M. J. Kovacs, M. Monreal et al., Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study, J. Thromb. Haemost, vol.13, issue.6, pp.1028-1035, 2015.

B. Mery, J. Guichard, J. Guy, A. Vallard, J. Barthelemy et al., Atrial fibrillation in cancer patients: Hindsight, insight and foresight, Int J Cardiol. 1 août, vol.240, pp.196-202, 2017.

S. Shah, F. L. Norby, Y. H. Datta, P. L. Lutsey, R. F. Maclehose et al., Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation, Blood Adv. 13 févr, vol.2, issue.3, pp.200-209, 2018.

D. Spirk, J. Ugi, W. Korte, M. Husmann, D. Hayoz et al., Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II, Thromb Haemost. Juin, vol.105, issue.6, pp.962-969, 2011.

T. Delate, D. M. Witt, D. Ritzwoller, J. C. Weeks, L. Kushi et al., Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer, Oncologist, vol.17, issue.3, pp.419-446, 2012.

S. R. Kahn, V. Springmann, S. Schulman, J. Martineau, J. A. Stewart et al., Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study, Thromb Haemost. sept, vol.108, issue.3, pp.493-501, 2012.

M. Sevestre, C. Belizna, C. Durant, J. Bosson, L. Vedrine et al., Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study, J Mal Vasc. mai, vol.39, issue.3, pp.161-169, 2014.

F. Cajfinger, P. Debourdeau, A. Lamblin, V. Benatar, N. Falvo et al., Low-molecularweight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study, Thromb Res. Août, vol.144, pp.85-92, 2016.

R. Belhadj-chaidi, C. Thollot, A. Ferru, P. Roblot, and C. Landron, Application des recommandations dans le traitement de la maladie thromboembolique veineuse chez les patients atteints de cancer : étude rétrospective sur 145 cas, Journal des Maladies Vasculaires. 1 mai, vol.38, issue.3, pp.185-92, 2013.

I. Puget, H. Buzzi, J. C. Lamuraglia, M. Chidiac, J. Strukov et al., Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study, Support Care Cancer, vol.105, issue.8, pp.3369-77, 2016.

A. Pillet, F. Minne, B. Chaidi, R. Chapelle, G. Ferru et al., Management of venous thromboembolism in cancer patients according to guidelines after educative measures, Bull Cancer. mai, vol.105, issue.5, pp.486-92, 2018.

R. D. Pineo, G. F. Brant, R. Liang, J. Cook, R. Solymoss et al., Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome, Am J Med, vol.122, issue.8, pp.762-769, 2009.

C. Cimminiello, A. Jr, and F. A. , Physician and patient perceptions of the route of adminis-tration of venous thromboembolism prophy-laxis: results from an international survey, Thromb Res, vol.129, issue.2, pp.139-184, 2012.

D. Farge, L. Bosquet, D. Kassab-chahmi, P. Mis-metti, I. Elalamy et al., French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group, Crit Rev Oncol Hematol, vol.73, issue.1, pp.31-46, 2008.
URL : https://hal.archives-ouvertes.fr/ujm-00439710

S. A. Hadley, M. Chang, and K. Rogers, Effect of syringe size on bruising following subcutaneous heparin injection, Am J Crit Care, vol.5, pp.271-277, 1996.

A. Nelson, D. Fitzmaurice, M. J. Bekkers, J. Baillie, and S. Sivell, A feasibility study to inform the design of a randomised con-trolled trial to identify the most clinically effective and cost-effective length of anticoagulation with low-molecular-weight heparin in the treatment of cancer-associated thrombosis (ALICAT), Health Technol Assess, vol.19, issue.83, pp.1-93, 2015.

P. W. Kamphuisen, Long-term treatment for cancer patients with deep venous thrombosis or pulmonary embolism (LONGHEVA)

J. Connault, S. Sadot, D. Cornuault, and C. Durant, Réunion de concertation pluridisciplinaire thrombose et cancer : l'expérience nantaise, J Mal Vasc, vol.40, issue.2, 2015.